MSA Safety (MSA)
NYSE: MSA
· Real-Time Price · USD
169.54
-0.65 (-0.38%)
At close: Aug 15, 2025, 3:59 PM
169.61
0.04%
After-hours: Aug 15, 2025, 05:52 PM EDT
-0.38% (1D)
| Bid | 167 |
| Market Cap | 6.64B |
| Revenue (ttm) | 1.83B |
| Net Income (ttm) | 276.97M |
| EPS (ttm) | 7.01 |
| PE Ratio (ttm) | 24.19 |
| Forward PE | 19.96 |
| Analyst | Hold |
| Ask | 170.35 |
| Volume | 308,890 |
| Avg. Volume (20D) | 268,928.3 |
| Open | 168.66 |
| Previous Close | 170.19 |
| Day's Range | 167.63 - 169.79 |
| 52-Week Range | 127.86 - 187.41 |
| Beta | 0.95 |
Analyst Forecast
According to 0 analyst ratings, the average rating for MSA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
MSA Safety is scheduled to release its earnings on
Oct 22, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
22 hours ago · proactiveinvestors.com
Tiziana Life Sciences doses first MSA patient in new trial – ICYMITiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi talked with Proactive about the company's latest milestone: dosing the first patient in its Phase 2a clinical trial targeting multiple system at...
1 day ago · proactiveinvestors.com
Tiziana Life Sciences doses first patient in Phase 2a MSA trialTiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has enrolled and dosed the first participant in its Phase 2a clinical trial evaluating intranasal foralumab in patients with Multiple System A...
1 week ago · fool.com
MSA (MSA) Earnings Beat EstimatesMSA (MSA) Earnings Beat Estimates
